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Abstract
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has been reported to elicit anti-proliferative response in
various tumors. In this study, we aim to investigate the antitumor effect of celecoxib on urothelial carcinoma (UC) cells and
the role endoplasmic reticulum (ER) stress plays in celecoxib-induced cytotoxicity. The cytotoxic effects were measured by
MTT assay and flow cytometry. The cell cycle progression and ER stress-associated molecules were examined by Western
blot and flow cytometry. Moreover, the cytotoxic effects of celecoxib combined with glucose-regulated protein (GRP) 78
knockdown (siRNA), (2)-epigallocatechin gallate (EGCG) or MG132 were assessed. We demonstrated that celecoxib
markedly reduces the cell viability and causes apoptosis in human UC cells through cell cycle G1 arrest. Celecoxib possessed
the ability to activate ER stress-related chaperones (IRE-1a and GRP78), caspase-4, and CCAAT/enhancer binding protein
homologous protein (CHOP), which were involved in UC cell apoptosis. Down-regulation of GRP78 by siRNA, co-treatment
with EGCG (a GRP78 inhibitor) or with MG132 (a proteasome inhibitor) could enhance celecoxib-induced apoptosis. We
concluded that celecoxib induces cell cycle G1 arrest, ER stress, and eventually apoptosis in human UC cells. The down-
regulation of ER chaperone GRP78 by siRNA, EGCG, or proteosome inhibitor potentiated the cytotoxicity of celecoxib in UC
cells. These findings provide a new treatment strategy against UC.
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Introduction
Bladder urothelial carcinoma (UC) ranks fourth in incidence
among cancers in men and eighth in women in the United States [1].
The prognosis for patients with metastatic UC remains poor [2].
Evenwithchemotherapeutictreatment,theoverallmediansurvivalis
about one year [2]. Cisplatin-based chemotherapy is the standard
treatment of patients with metastatic UC; however, despite regimens
such as the cisplatin, gemcitabine or paclitaxel combination, the
overall response rates vary between 40% and 65% [3–5]. The other
limiting factor associated with current chemotherapeutic regimens is
the substantial toxicities. Therefore, there is an urgent need for the
development of novel therapeutic agents for UC treatment.
Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2)
and is widely used for anti-inflammation or pain control.
Considerable preclinical evidence supports the potential of
celecoxib against several types of malignancies [6]; however, the
utility of celecoxib by itself or in combination with other therapies
for treating UC has not been fully explored [7–10]. Several studies
have reported that celecoxib possesses the anti-tumor effect in the
absence of COX-2 involvement [8,11]. The previous studies have
shown that anti-tumor mechanisms of celecoxib may include the
death receptors, mitochondria-mediated pathways, cell cycle arrest,
Akt phosphorylation inhibition, endoplasmic reticulum (ER) stress,
and autophagy [8,11–17]. The exact underlying mechanisms of the
anti-tumor effects mediated by celecoxib remain unclear.
Theunfolded proteinresponse(UPR) is a cellular stress response of
the ER. The ER stress response is activated in response to an
accumulation of unfolded or misfolded proteins in the lumen of the
ER [18–20]. These unfolded proteins can be removed by ER-
associated degradation (ERAD), which delivers abnormal proteins to
the proteasomes [19,21–22]. In this study, we try to investigate the
role of UPR in celecoxib-induced cytotoxicity in human bladder UC
cells.Wealsoexamine whether the interference of UPR pathway can
enhance the celecoxib-induced cytotoxicity in UC cells.
Materials and Methods
Cell culture
We have performed the experiments on three cell lines. SV-
HUC cells were the SV40 transformed immortalized, non-
tumorigenic human urothelial cell line [23]. NTUB1 cells were
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specimen of a 70-year-old female patient with high grade
transitional cell carcinoma and was proved to be tumorigenic in
nude mice [24–25]. The T24 cells were derived from a highly
malignant grade III human urinary bladder carcinoma (Figure
S1). NTUB1 cells were kindly provided from Dr. Yeong-Shiau Pu
(Department of Urology, National Taiwan University Hospital,
Taipei, Taiwan). T24 human UC cell line was obtained from the
American Type Culture Collection (Manassas, VA). SV-HUC
cells were kindly provided from Dr. Tai-Lung Cha (Department of
Urology, Tri-Service General Hospital and National Defense
Medical Center, Taipei, Taiwan). Cells were maintained at 37uC
in RPMI-1640 medium (for NTUB1 cells), Dulbecco’s Modified
Eagle Medium (for T24 cells) or F12 (for SV-HUC) supplemented
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and
100 mg/mL streptomycin (Invitrogen, Carlsbad, CA).
Reagents and antibodies
Celecoxib pure compound was provided by Pfizer (New York,
NY). Various concentrations of celecoxib were prepared as
suspensions in DMSO (Sigma-Aldrich, St. Louis, MO) and then
mixed with cell medium containing 10% FBS. LM-1685, a
celecoxib analogue, is another COX-2 inhibitor purchased from
Calbiochem (San Diego, USA). (2)-Epigallocatechin gallate
(EGCG) and MG132 (a proteasome inhibitor) were purchased
from Sigma-Aldrich (San Diego, USA). Antibodies against various
proteins for Western blot analysis such as poly (ADP-ribose)
polymerase (PARP), cleaved PARP, caspase-3, 4, 7, 8, 9, cleaved
caspase-3, 7, 8, 9, p21, p27, IRE-1a, GRP78, CHOP, and calnexin
were obtained from Cell Signaling Technologies (Danvers, MA).
Other antibodies against ubiquitin, b-actin and a-tubulin were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and
anti-GAPDH antibody was purchased from Genetex (Irvine, CA).
Figure 1. Celecoxib reduces cell viability and induces apoptosis in UC cells and SV-HUC cells. (A) Cells were treated with various
concentrations of celecoxib for 24 h. Cell viability was assessed by MTT assay. (B) Cells were exposed to mock (untreated) and 100 mM celecoxib for
24 h. Apoptotic cells were analyzed by FACS flow cytometry with propidium iodide (PI) and annexin V-FITC staining. The lower-right panel presented
annexin V-positive cells (early apoptotic cells); the upper-right panel presented late apoptotic cells with membranes permeable to PI and annexin V
staining. (C) Quantitative analysis of total apoptosis (early and late) population following 100 mM celecoxib treatment was presented. In (A) and (C),
data are presented as means 6 SD of three independents experiments. * p,0.05 as compared with control. In (B), results shown are representative of
at least three independent experiments.
doi:10.1371/journal.pone.0033615.g001
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Cell viability was determined by using 3-(4,5-dimethylthiazol-2-
yl)- 2,5-diphenyl tetrazolium (MTT, Sigma-Aldrich). In brief, cells
were seeded with culture medium in 96-well microplates (4500
cells/well) and incubated at 37uC for 24 h before drug exposures.
At the end of treatments with drugs, cells were incubated with
completed-medium containing 0.4 mg/ml MTT at 37uC for 4 h.
The reduced MTT crystals were dissolved in DMSO and the
absorbance was detected at 570 nm with a plate reader.
Immunoblotting
After various treatments, the NTUB1 and T24 cells were
washed with cold phosphate buffered saline (PBS) and then lysed
with cell lysis buffer (Cell Signaling Technologies) on ice. The cell
lysates were centrifuged at 14000 rpm for 30 min at 4uC. The
supernatants were collected and the concentrations of the proteins
were determined by BCA protein assay (Thermo Scientific Pierce,
Rockford, IL). Equal quantity of each samples were resolved in
SDS-polyacrylamide then transfer to polyvinylidene fluoride
Figure 2. Celecoxib caused cell cycle arrest at G1 phase in NTUB1 and T24 UC cells. (A) NTUB1 and T24 cells were treated with mock
(untreated) or celecoxib (100 mM) for 12 and 24 h, and cell cycle analysis was measured as described in Materials and methods. Data are presented as
means 6 SD of three independents experiments. * p,0.05 as compared with control. (B) The expressions of p21 and p27 at 12 and 24 h after
celecoxib treatment were analyzed by Western blotting. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0033615.g002
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were incubated with 5% skim milk in PBS and then incubate
appreciate amount of primary antibodies in PBS at 4uC overnight.
The membranes were then washed twice with PBST (PBS
containing 0.05% Tween 20) and incubated at room temperature
for 1 h with applicable horseradish peroxidase (HRP)-conjugated
secondary antibodies (Genetex) at appropriate dilution ratios in
PBS. After washed twist with PBST, antibody bound-membranes
were visualized by enhanced chemiluminescence western blotting
detection reagents (Millipore).
Knockdown of GRP78 by using siRNA
For knockdown of GRP78, the cells were transfected with small
interfering RNA (siRNA) against GRP78. NTUB1 and T24 cells
were transfected with various concentrations of siRNA for GRP78
(Thermo Scientific Dharmacon, Lafayette, CO) or nonsilencing
scramble siRNA with the use of SiLenFect (Bio-Red) according to
the manufacturer’s instructions. The transfected cells were incubat-
ed with or without 100 mM celecoxib in complete medium for 24 h.
Analysis of apoptosis by fluorescence-activated cell
sorting (FACS)
Cells were stained with annexin V-FITC apoptosis detection kit
(Strong Biotech, Taipei, Taiwan), and apoptotic cells identified
and quantified by flow cytometry. Briefly, after exposing to
different treatments, NTUB1 and T24 cells were washed with PBS
and then harvested by trypsin-EDTA solution (Invitrogen). The
cell suspensions were centrifuged at 1000 rpm for 5 min to remove
trypsin-EDTA solution. Then the cells were re-suspended and
incubated with propidium iodide (PI), annexin V-FITC, and
annexin V binding buffer for 15 min at room temperature. The
stained cells were analyzed on a FACS flow cytometry (Becton
Dickinson Cockeysville, MD).
Cell cycle analysis by flow cytometry
NTUB1 and T24 cells were grown in medium as mentioned
above. At 50% confluency, cells were treated with DMSO control or
100 mM celecoxib for 24 h. Cells were collected and processed for
cell cycle analysis. Briefly, 0.5610
5 cells were suspended in 0.5 mL of
PI solution, and incubated 30 min in the dark. Cell cycle distribution
was then analyzed by FACS flow cytometry (Becton Dickinson).
Statistical analysis
The GraphPad PrismH 4 software was used to perform all data
analysis. All data were expressed as mean 6 SD and analyzed by
one-way ANOVA followed by Bonferroni post hoc test, with
values of P,0.05 considered statically significant.
Results
Celecoxib affected viability, apoptosis, GRP78 protein
expression, and cell cycle in human UC cells
We first assessed the effect of celecoxib on the viability of human
UC cell lines (NTUB1 and T24) and SV-HUC cells using the
Figure 3. Effects of celecoxib on the ER stress-related signaling molecules IRE-1a, GRP78, CHOP, and caspase-4 in NTUB1 and T24
cells. In (A) and (B), NTUB1 cells were exposed to mock (untreated) and 100 mM celecoxib. The cell lysates were harvested at each time point and
analyzed by Western blotting with specific antibodies to detect ER stress-related molecules IRE-1a, CHOP, calnexin, GRP78, and caspase-4,. CF is the
abbreviation of cleaved form. (C) and (D) showed the similar experiments performed in T24 cells. Results shown are representative of at least four
independent experiments.
doi:10.1371/journal.pone.0033615.g003
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viability in a dose-dependent manner in NTUB1 and T24 cells
and had no significant effect on cell viability of SV-HUC
(Figure 1A). Moreover, apoptotic cells were analyzed by flow
cytometry (FACS) with propidium iodide (PI) and Annexin V-
FITC staining. Celecoxib (100 mM) markedly induced the cell
apoptosis in NTUB1 and T24 cells after 24 h exposure (Figures 1B
and C).
Next, we determined whether celecoxib has a cell cycle arrest
effect in human UC cells. Celecoxib-treated UC cells were blocked
in the G1 phase after 12 and 24 h treatment (Figure 2A).
Moreover, the expressions of Cdk inhibitor proteins p21 and p27
in NTUB1 and T24 cells were markedly increased at 12 and 24 h
after exposure to celecoxib (100 mM) (Figure 2B).
Celecoxib induced ER stress in human UC cells
Celecoxib has been reported to induce ER stress in several types of
cancer cells [12,17,26–27]. Here, we found that treatment of NTUB1
and T24 cells with 100 mM celecoxib could also induce ER stress
(Figure 3). During the 24 h exposure, celecoxib induced the protein
expressions of IRE-1a,GR P7 8 ,a ndC H OPan dt hec le av a geo fc as p a se -
4 in NTUB1 (Figures 3A and 3B) and T24 cells (Figures 3C and 3D). In
addition, the suppression of calnexin was also shown after celecoxib
(100 mM) treatment in NTUB1 (Figure 3A) and T24 cells (Figure 3C).
Figure 4. The combinative effects of celecoxib and GRP78 knockdown on apoptosis of NTUB1 and T24 cells. (A) Cells were transfected
with GRP78 siRNA (10 nM) or scramble siRNA (10 nM) (as a control); then treated with 100 mM celecoxib. The combinative effect of celecoxib and
GRP78 knockdown on apoptosis was determined by flow cytometry (FACS) with annexin V-FITC and PI labeling in (a). (b) Quantitative analysis of total
apoptosis (early and late) population was presented. Data are presented as means 6 SD of three independents experiments. * p,0.05 as compared
with scramble siRNA+celecoxib. (B) Cells were transfected with 10, 15 and 20 nM GRP78 siRNA, and 20 nM scramble siRNA as control; then treated
with 100 mM celecoxib. Cell lysates were harvested and analyzed by Western blotting with specific antibodies against GRP78, caspase-3, 8, cleaved
caspase-3, 8 (a), caspase- 9, 7, cleaved caspase-7, 9, PARP and cleaved PARP (b). CF is the abbreviation of cleaved form. Results shown are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0033615.g004
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apoptosis in human UC cells
GRP78 has been reported to be associated with chemoresistance
[28–29]. The celecoxib-induced expression of GRP78 raises a
question concerning the relationship between GRP78 expression
and apoptosis in NTUB1 and T24 cells. To clarify this issue, we
used the siRNA approach to examine the role GRP78 in celecoxib-
induced apoptosis in NTUB1 and T24 cells (Figure 4A). Transfec-
tion of GRP78 siRNA, which actually decreased the protein
expression of GRP78 (Figure 4B), significantly enhanced the
increase of cell apoptosis (Figures 4A) and the cleavage of caspases
and PARP (Figures 4B) in celecoxib (100 mM)-treated NTUB1 and
T24 cells. These results indicate that GRP78 expression may be
correlated to the chemoresistance to celecoxib in human UC cells.
Treatment with EGCG, a known GRP78 inhibitor,
potentiatedcelecoxib-inducedapoptosisinhumanUCcells
Recently, several compounds have been discovered to be
GRP78 antagonists and have anticancer activity [28–29]. These
compounds worked in synergy with chemotherapeutic drugs to
reduce tumor growth. EGCG has been reported to bind to the
ATP binding domain of GRP78 and thereby blocks its function
[29–30]. Here, we investigated the apoptosis induction effect of
EGCG in combination with celecoxib on NTUB1 and T24 cells.
As shown in Figure 5A, treatment with EGCG promotes
celecoxib-induced apoptosis in NTUB1 and T24 cells. The
combinative treatment of EGCG induced down-regulation of
GRP78 and enhanced the celecoxib-induced cytotoxicity in
NTUB1 and T24 cells (Figure 5B and C).
Figure 5. The combinative effects of celecoxib and EGCG on apoptosis in NTUB1 and T24 cells. Cells were incubated in the presence of
100 mM celecoxib and EGCG (10, 20, 33.3 and 40 mM) individually or in combination. (A) Cells were stained with annexin V-FITC and PI for apoptosis
analysis by FACS flow cytometry. Results shown are representative of at least three independent experiments. Data are presented as means 6 SD of
three independents experiments. * p,0.05 as compared with celecoxib alone. (B) and (C) Cell lysates were harvested and analyzed by Western
blotting with specific antibodies against caspase-3, 7, 8, 9, PARP, GRP78, and CHOP. CF is the abbreviation of cleaved form. Results shown are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0033615.g005
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To reduce UPR, the proteasome pathway plays a role in the
degradation of unfolded protein [21,26,31]. It is conceivable that
inhibition of proteasome may aggravate celecoxib-induced cell
apoptosis due to the accumulation of unfolded protein. To test this
issue, we examined the combinative effect of celecoxib and
proteasome inhibitor, MG132, on NTUB1 and T24 cells. At low
dose (0.5 and 1 mM), MG132 did not affect cell viability, whereas
the combination of celecoxib and MG132 enhanced the cell death
(Figure 6A), apoptosis (Figures 6B and 6C), and the cleavages of
caspases and PARP (Figure 6D) in NTUB1 and T24 cells.
Moreover, MG132 could furthermore increase celecoxib-induced
ubiquitin and CHOP and downregulate GRP78 expressions in
NTUB1 and T24 cells (Figure 6E). These findings also indicated
that proteosome inhibitor MG132 aggravated the celecoxib-
induced unfolded protein stress and potentiate the ER stress-
related apoptosis.
GRP78 knockdown sensitize LM-1685, a non-coxib COX-2
inhibitor, -induced apoptosis in human UC cells
On the contrary, celecoxib analogue LM-1685, a non-coxib COX-2
inhibitor, had no inhibitory effects on the viability of NTUB1 and T24
cells (Figure 7A). LM-1685 did not induce the expression of ER stress-
related molecules after 24 h treatment (Figure 7B). Transfection with
GRP78 siRNA significantly enhanced the apoptotic effect of LM-1685
in NTUB1 and T24 UC cells (Figure 7C). We believed that down-
regulation of GRP78 could sensitize the drug resistance of LM-1685 to
UC cells. These findings suggest the critical role of GRP78 on the
survival of UC cells after COX-2 inhibitor treatment.
Figure 6. The combinative effect of celecoxib and MG132 on cell growth and apoptosis in NTUB1 and T24 cells. Cells were incubated
in the presence of 100 mM celecoxib and MG132 (0.5 and 1 mM) individually or in combination. (A) Cell viability was measured by MTT assay. (B) Cells
were stained with annexin V-FITC and PI for apoptosis analysis by FACS flow cytometry. (C) Quantitative analysis of total apoptosis (early and late)
population was presented. (D) and (E) Cells were incubated in the presence of 100 mM celecoxib and MG132 (1 mM) individually or in combination.
Cell lysates were harvested and analyzed by Western blotting with specific antibodies against, caspase-3, 7, 8, 9, PARP, CHOP, GRP78, and ubiquitin. In
A and C, data are presented as means 6 SD of three independents experiments. * p,0.05 as compared with celecoxib alone. In B and D, results
shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0033615.g006
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and T24 cells. (A) Cells were treated with LM-1685 (0–160 mM) for 24 h. Cell viability was analyzed by MTT assay. Data are presented as means 6 SD
of three independents experiments. (B) Cells were treated with LM-1685 (80 and 160 mM) or celecoxib (100 mM) for 24 h. The cell lysates were
harvested at each time point and analyzed by Western blotting with specific antibodies to detect ER stress-related molecules IRE-1a, CHOP, calnexin,
and GRP78, and caspase-4. CF is the abbreviation of cleaved form. (C). Cells were transfected with GRP78 siRNA (10 nM) or scramble siRNA (10 nM) (as
a control), and then treated with 160 mM LM-1685. The combinative effect of LM-1685 and GRP78 knockdown on apoptosis was determined by flow
cytometry (FACS) with annexin V-FITC and PI labeling. The quantitative analysis of total apoptosis (early and late) population was presented. Data are
presented as means 6 SD of three independents experiments. * p,0.05 as compared with scramble siRNA+LM-1685.
doi:10.1371/journal.pone.0033615.g007
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Systemic chemotherapy is the only modality to improve the
survival in patients with metastatic UC. However, the treatment of
metastatic UC by cytotoxic chemotherapy has reached a therapeu-
tic plateau. To search for novel treatment modalities is imperative.
COX-2 inhibitors have been studied in pre-clinical investigation as
therapeutic or chemo-preventive agents in various cancers [7–8,11–
13,15]. However, the treatment efficacy of COX-2 inhibitors in UC
has not been fully explored [7–8,32–34]. In this study, we showed
that celecoxib is capable of inducing the ER stress, apoptosis, and
cell death in human UC cells. GRP78 knockdown by siRNA,
GRP78 inhibitor, or proteasome inhibitor effectively enhanced the
celecoxib-induced caspases-regulated UC cell apoptosis.
The UPR can induce the transcription of genes encoding ER-
resident chaperones to facilitate protein folding. Meanwhile, the
ERAD can be activated to degrade the unfolded proteins
accumulated in the ER [21–22]. The goal of UPR is to alleviate
the cellular stress and restore proper ER homeostasis. However, if
the ER stress persists intensely, these signaling pathways can
trigger cell apoptosis [19–20]. In mammalian cells, signaling
molecules PERK, IRE-1a, and ATF6 sense the presence of
unfolded proteins in the ER lumen and transduce the signals to the
cytoplasm and the nucleus [19,35]. GRP78 is a main regulator of
the pro-survival pathway in the UPR and plays an important role
in protein folding and assembly [19,35]. Aggregation of unfolded
proteins resulted in the ER stress induction that GRP78 dissociates
from the three ER transmembrane receptors (PERK, ATF-6, and
IRE-1a), which leads to their activation and triggers the UPR
[18,20]. The activated PERK pathway induces downstream
CHOP expression, and then triggered the cell apoptosis. Calnexin,
an ER transmembrane chaperone, plays the key roles in
translocation, protein folding, and quality control of newly
synthesized polypeptides [18,20].
The roles of GRP78 in tumor formation, progression and
angiogenesis have been demonstrated [29,35]. Drug resistance of
cancer cells to a broad range of therapeutic agents, many of which
are not directly linked to ER stress, has been attributed to GRP78.
GRP78 has been shown to reduce the ER stress-related cancer cell
apoptosis [28,35]. Constitutive over-expression of GRP78 has also
been reported to confer chemo-resistance in cancer therapy
[28–29]. Down-regulation of GRP78 by siRNA or chemical
inhibition has been shown to enhance the chemo-sensitivity in
tumor-associated endothelial cells [29]. Recently, several com-
pounds have been shown to be GRP78 inhibitors, which have
anticancer activity and work in synergy with chemotherapeutic
drugs to reduce tumor growth [28–30]. Chemo-resistance remains
a major challenge in treatment of metastatic UC. Identifying
mechanisms of drug resistance and development of new
therapeutic agent are important in treatment of UC [2]. In this
study, exposure of human UC cells to celecoxib actually induces
UPR activation. The celecoxib-induced UPR in human UC cells
is associated with the up-regulation of GRP78. GRP78 knockdown
by using siRNA or chemical inhibition (EGCG) could potentiate
the cytotoxic and apoptotic effect of celecoxib in UC cells.
Moreover, LM1685 did not up-regulate GRP78 as celecoxib, nor
did it induce cytotoxicity in human UC cells. However, GRP78
knockdown did effectively enhance celecoxib cytotoxicity and
reverse resistance to LM1685. Our findings indicate the critical
role of GRP78 in protecting cancer cells from COX-2 inhibitor-
induced apoptosis. Down-regulation of GRP78 can significantly
enhance the susceptibility to COX-2 inhibitor in UC cells.
The ubiquitin proteosome pathway is another pathway for
intracellular protein degradation to maintain homeostasis during
cell encounter the UPR stress [31]. A previous study has shown that
a combination of celecoxib and proteosome inhibitor MG132
provides synergistic anti-proliferative effect in human liver tumor
cells [21]. In the present study, we found that combined treatment
withMG132 in human UC cells could potentiate celecoxib-induced
cytotoxicity with concomitant down-regulation of GRP78.
Celecoxib is commonly administered orally with dosage of
200 mg twice daily, resulting in mean peak serum concentration of
1–2 mM [36]. Reported side effects of celecoxib in therapeutic
dosage include cardiovascular thrombosis, congestive heart failure,
gastrointestinal ulceration, renal or hepatic injury, and platelet
aggregation [37]. Some reports on side effects of celecoxib in
supratherapeutic dosage in clinical trial showed that there were no
significant side effects in supratherapeutic dosage [38]. In our
study, using in vitro methods, we chose 100 mM as the working
concentration of celecoxib, a concentration much higher than the
concentration corresponding to the FDA recommended maximal
dose. This is in line with a variety of studies on the anti-tumor
effect of celecoxib in vitro showing that the concentration of
celecoxib needed to inhibit growth of cancer cells in vitro is much
higher than that needed in vivo for bladder and other cancers
[7–8,10,39–42]. This discrepancy indicates that tumor growth in
vivo is determined by interactions between factors intrinsic to
tumor cells and extrinsic factors such as the extracellular matrix,
stromal cells, and other host factors. These extrinsic factors are
generally absent under in vitro conditions. Cell culture models are
often used to evaluate the therapeutic potential of COX-2
inhibitors against cancer, but it must be noted that in vitro results,
particularly as relates to relative dose of agent used, cannot be
directly extrapolated to the whole organism (in vivo) [42].
In conclusion, the present study showed that celecoxib can
significantly inhibit the proliferation of human UC cells. The
aggravated unfolded protein stress caused by down-regulation of
GRP78 or by proteasome inhibitor will further enhance the
celecoxib-induced UC cell apoptosis. These findings are promising
and warrant further study for the development of new therapeutic
strategies against UC.
Supporting Information
Figure S1 Both T24 and NTUB1 cells showed high level
of COX-2 and GRP78 expression.
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